# Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis

> **NCT01191996** · PHASE1,PHASE2 · COMPLETED · sponsor: **Innate Immunotherapeutics** · enrollment: 34 (actual)

## Conditions studied

- Secondary Progressive Multiple Sclerosis
- Primary Progressive Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** MIS416

## Key facts

- **NCT ID:** NCT01191996
- **Lead sponsor:** Innate Immunotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-06
- **Final completion:** 2012-11
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2012-12-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01191996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01191996, "Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01191996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*